Cardioprotective Properties of the Platelet P2Y12 Receptor Inhibitor, Cangrelor: Protective in Diabetics and Reliant Upon the Presence of Blood

Cardiovascular Drugs and Therapy

Volumn 29, Issue 5, 2015, Pages 415-418

  Bell, R M ^a   Sivaraman, V ^a   Kunuthur, S P ^a   Cohen, M V ^b   Downey, J M ^b   Yellon, D M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

Anti platelet; Cangrelor; Cardioprotection; Ischaemia; P2Y12 inhibitor; Reperfusion injury

Indexed keywords

CANGRELOR; GLUCOSE; PURINERGIC P2Y12 RECEPTOR; ADENOSINE PHOSPHATE; CARDIOTONIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ACUTE CORONARY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC PATIENT; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CRYSTALLOID; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG MECHANISM; EX VIVO STUDY; GLUCOSE BLOOD LEVEL; HEART INFARCTION SIZE; HEART PROTECTION; HYPERGLYCEMIA; IN VIVO STUDY; INSULIN RESISTANCE; ISCHEMIC PRECONDITIONING; LONG TERM EXPOSURE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; COMPLICATION; DIABETES COMPLICATIONS; DOSE RESPONSE; DRUG EFFECTS; HUMAN; INBRED RAT STRAIN; METABOLISM; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; THROMBOCYTE;

ADENOSINE MONOPHOSPHATE; ANIMALS; BLOOD PLATELETS; CARDIOTONIC AGENTS; DIABETES COMPLICATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MICE; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RATS; RATS, INBRED STRAINS; RECEPTORS, PURINERGIC P2Y12;

EID: 84946496589     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-015-6609-2     Document Type: Article

References (8)

1. Yang XM, Liu Y, Cui L, et al. Platelet P2Y(1)(2) blockers confer direct postconditioning-like protection in reperfused rabbit hearts. J Cardiovasc Pharmacol Ther. 2013;18:251–62.
2. Ferri N, Corsini A, Bellosta S. Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties. Drugs. 2013;73:1681–709.
3. Parodi G, Valenti R, Bellandi B, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol. 2013;61:1601–6.
4. Hausenloy DJ, Ong SB, Yellon DM. The mitochondrial permeability transition pore as a target for preconditioning and postconditioning. Basic Res Cardiol. 2009;104:189–202.
5. Whittington HJ, Harding I, Stephenson CI, et al. Cardioprotection in the aging, diabetic heart: the loss of protective Akt signalling. Cardiovasc Res. 2013;99:694–704.
6. Yang XM, Liu Y, Cui L, et al. Two classes of anti-platelet drugs reduce anatomical infarct size in monkey hearts. Cardiovasc Drugs Ther. 2013;27:109–15.
7. Yang XM, Cui L, Alhammouri A, et al. Triple therapy greatly increases myocardial salvage during ischemia/reperfusion in the in situ rat heart. Cardiovasc Drugs Ther. 2013;27:403–12.
8. Goto Y, Kakizaki M, Masaki N. Production of spontaneous diabetic rats by repetition of selective breeding. Tohoku J Exp Med. 1976;119:85–90.